COVID-19 after rituximab therapy in cSLE patients

Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Meghan Corrigan, Manos, Cynthia K., Flanagan, Elaine, Prahalad, Sampath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/
https://www.ncbi.nlm.nih.gov/pubmed/37362155
http://dx.doi.org/10.1177/25151355231181242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285438/
https://www.ncbi.nlm.nih.gov/pubmed/37362155
http://dx.doi.org/10.1177/25151355231181242

Ejemplares similares